368 related articles for article (PubMed ID: 36427341)
1. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
[No Abstract] [Full Text] [Related]
2. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
[TBL] [Abstract][Full Text] [Related]
3. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
5. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
6. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting.
Bogart M; Glassberg MB; Reinsch T; Stanford RH
Respir Med; 2018 Dec; 145():138-144. PubMed ID: 30509702
[TBL] [Abstract][Full Text] [Related]
7. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
[No Abstract] [Full Text] [Related]
8. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.
Coutinho AD; Lokhandwala T; Boggs RL; Dalal AA; Landsman-Blumberg PB; Priest J; Stempel DA
Int J Chron Obstruct Pulmon Dis; 2016; 11():1223-31. PubMed ID: 27354781
[TBL] [Abstract][Full Text] [Related]
9. Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study.
Strange C; Tkacz J; Schinkel J; Lewing B; Agatep B; Swisher S; Patel S; Edwards D; Touchette DR; Portillo E; Feigler N; Pollack M
Int J Chron Obstruct Pulmon Dis; 2023; 18():2245-2256. PubMed ID: 37849918
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
11. Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.
Czira A; Akiyama S; Ishii T; Wood RP; Camidge LJ; Wallis H; Jennison T; Wild RAC; Yarita M; Hashimoto K; Rothnie KJ; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():2933-2953. PubMed ID: 38089540
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Triple Therapy Treatment Pathways in Chronic Obstructive Pulmonary Disease (COPD): A Machine-Learning Predictive Model.
Bogart M; Liu Y; Oakland T; Stiegler M
Int J Chron Obstruct Pulmon Dis; 2022; 17():735-747. PubMed ID: 35418750
[TBL] [Abstract][Full Text] [Related]
14. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
15. Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study.
Yamada H; Matsumoto I; Makita N; Arita Y; Hayashi N; Mitsuoka K; Tashiro N; Hizawa N
Respir Res; 2022 Sep; 23(1):255. PubMed ID: 36123707
[TBL] [Abstract][Full Text] [Related]
16. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
17. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β
Wittbrodt ET; Millette LA; Evans KA; Bonafede M; Tkacz J; Ferguson GT
Int J Chron Obstruct Pulmon Dis; 2019; 14():101-114. PubMed ID: 30613140
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission.
Tran M; Xiang P; Rascati KL; Stock EM; Godley PJ; Coleman A; Bogart MR; Stanford RH
J Manag Care Spec Pharm; 2016 Oct; 22(10):1186-93. PubMed ID: 27668567
[TBL] [Abstract][Full Text] [Related]
20. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]